Natera partners with Diakonos to track fast-tracked melanoma immunotherapy

Natera (NASDAQ:TRA) has entered into a clinical collaboration with Diakonos Oncology to deploy its liquid biopsy technology to track patient responses during an active trial for an aggressive skin cancer therapy.

Under the terms of the agreement, Natera’s Signatera molecular residual disease platform will be used to longitudinally assess circulating tumor DNA (ctDNA) in patients participating in the DOC-RM Phase I/II clinical trial.

The study evaluates Diakonos’s flagship investigational immunotherapy, DOC1021 (dubodencel), in individuals diagnosed with refractory, unresectable, or metastatic cutaneous melanoma.

Refractory melanoma remains a persistent hurdle in advanced oncology.

While conventional checkpoint inhibitors have significantly altered treatment paradigms for skin cancers, many patients develop resistance or fail to respond entirely.

The trial, which opened enrollment in May, aims to utilize cell-free DNA tracking to uncover early biological signals of therapeutic impact or disease progression.

Evaluating treatment efficacy in immunotherapy trials frequently presents a challenge for clinicians using traditional diagnostics.

Standard radiographic scans can lag behind actual tumor biology or produce ambiguous results because of localized immune inflammation, a phenomenon often referred to as pseudoprogression.

Assessing molecular responses via serial blood draws offers an earlier window into tumor dynamics during and immediately following treatment.

The investigational therapy, DOC1021, is a personalized, first-in-class dendritic cell treatment.

The platform is designed to act as a physiologic mimic of a viral infection, utilizing a patient’s own immune cells to target the complete antigen pool of the tumor.

The U.S. Food and Drug Administration recently granted Fast Track status to the candidate for advanced melanoma, marking its third such regulatory designation following prior awards in pancreatic cancer and glioblastoma.

For Natera, the agreement expands the commercial and clinical footprint of its biopharma partnering division into emerging cellular immunotherapies.

The California-based molecular diagnostics specialist has steadily positioned its customized assays as core diagnostic tools for assessing secondary endpoints in oncology drug development.